Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Kevin Shalayda"'
Autor:
Prasarn Manitpisitkul, Michael Brandt, Christopher M. Flores, Velga Kenigs, John A. Moyer, Gary Romano, Kevin Shalayda, Arthur J. Mayorga
Publikováno v:
PAIN Reports, Vol 1, Iss 4, p e576 (2016)
Abstract. This double-blind, randomized, placebo-controlled, sequential group, phase 1 study was designed to assess in healthy men, the safety, tolerability, pharmacokinetics, and translational pharmacodynamics of JNJ-39439335 (mavatrep), a transient
Externí odkaz:
https://doaj.org/article/e5d8331f05dd486285cf40982c6c5af0
Autor:
Jocelyn H. Leu, Xin Miao, Kevin Shalayda, Kevin J. Coe, Ariane Kahnt, Bonnie Wu, Megan Schnarr, Carol Franks, James Devlin, Tong‐Yuan Yang, James A. Palmer, Mai Zhang, Honghui Zhou, Wim Van Damme, Sophie Smets, Zuleima Aguilar, Sandra R. Chaplan
Publikováno v:
Clinical Pharmacology in Drug Development.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d4bbe9e75b30d3159200720f0b809dd
https://doi.org/10.1002/cpdd.1253
https://doi.org/10.1002/cpdd.1253
Autor:
Joseph Caruso, Prasarn Manitpisitkul, Lucille Russell, Kevin Shalayda, Panna Sanga, John A. Moyer, Bhavna Solanki, Yinka Williams
Publikováno v:
Clinical Pharmacology in Drug Development. 7:699-711
To improve room temperature stability and oral bioavailability of mavatrep (JNJ-39439335, a transient receptor potential vanilloid subtype-1 antagonist), various formulations were initially developed and evaluated in 2 phase 1 open-label, randomized,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::191819b167cde1d3331c1c34d950c2dc
https://doi.org/10.1002/cpdd.412
https://doi.org/10.1002/cpdd.412
Autor:
Christopher M. Flores, Arthur J. Mayorga, Gary Romano, John A. Moyer, Kevin Shalayda, Prasarn Manitpisitkul, James S Hutchison, Kanaka Tatikola
Publikováno v:
Scandinavian journal of pain. 18(2)
Background and aims: This double-blind (DB), randomized, placebo-controlled, sequential-group, multiple-ascending dose, phase 1 study evaluated safety, pharmacokinetics and pharmacodynamics of JNJ-39439335 in healthy men (part 1), and in participants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c892c7855d268e467d20d6a0b80309d
https://pubmed.ncbi.nlm.nih.gov/29794306
https://pubmed.ncbi.nlm.nih.gov/29794306
Autor:
Joseph Caruso, John A. Moyer, Lucille Russell, Kevin Shalayda, Yuki Iwaki, Prasarn Manitpisitkul, Panna Sanga, Bhavna Solanki
Publikováno v:
Clinical pharmacology in drug development. 7(7)
This single-center, double-blind, placebo-controlled, sequential-group phase 1 study evaluated the safety, tolerability, and pharmacokinetics (PK) of mavatrep (JNJ-39439335), a transient receptor potential vanilloid 1 antagonist, in healthy Japanese
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51eb03f27cafe1ed7a0205ae85153546
https://pubmed.ncbi.nlm.nih.gov/29125703
https://pubmed.ncbi.nlm.nih.gov/29125703
Autor:
Jeremiah J. Trudeau, Nathaniel P. Katz, Stuart H. Ratcliffe, Gary Romano, Christopher M. Flores, Roi Treister, Prasarn Manitpisitkul, John A. Moyer, Arthur J. Mayorga, Kevin Shalayda, Mary Ellen Frustaci, Mark C. Dale
Publikováno v:
Scandinavian journal of pain. 17
Background/AimsTransient receptor potential vanilloid type 1 (TRPV1) receptor antagonists have been evaluated in clinical studies for their analgesic effects. Mavatrep, a potent, selective, competitive TRPV1 receptor antagonist has demonstrated pharm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31d6b22733dc4d1c202ba3ff7494de73
https://pubmed.ncbi.nlm.nih.gov/28961519
https://pubmed.ncbi.nlm.nih.gov/28961519
Autor:
Kevin Shalayda, Christopher R. Curtin, Donald Heald, Prasarn Manitpisitkul, Lisa Ford, Shean-Sheng Wang
Publikováno v:
Epilepsy Research. 108:891-901
Topiramate is primarily renally excreted. Chronic renal and hepatic impairment can affect the clearance of topiramate. Therefore, the objective was to establish dosage guidelines for topiramate in chronic renal impairment, end-stage renal disease (ES
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc646f8723b8992093c473fa37eb5563
https://doi.org/10.1016/j.eplepsyres.2014.03.011
https://doi.org/10.1016/j.eplepsyres.2014.03.011
Autor:
Shean-Sheng Wang, Lisa Ford, Prasarn Manitpisitkul, Christopher R. Curtin, Kevin Shalayda, Donald Heald
Publikováno v:
Clinical Pharmacology in Drug Development. 3:378-387
Drug-drug interactions between topiramate and diltiazem, hydrochlorothiazide, or propranolol were evaluated along with safety/tolerability in three open-label studies. Healthy participants (aged 18-45 years) received topiramate 75 mg every 12 hours (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b21a1581db3414cff3a1bf584f014951
https://doi.org/10.1002/cpdd.107
https://doi.org/10.1002/cpdd.107
Publikováno v:
Journal of Pediatric Neurology and Medicine. 1
Background: An integrated analysis of five randomized, placebo-controlled studies in migraine prophylaxis was conducted to assess topiramate’s efficacy and safety in pediatric patients. Methods: Study 1, a pivotal study (50-, 100 mg/day; aged 12-17
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c22985c003ac0f1f16491c7c22f333d
https://doi.org/10.4172/2472-100x.1000112
https://doi.org/10.4172/2472-100x.1000112
Publikováno v:
Epilepsia. 54:156-164
Summary Purpose: To characterize the pharmacokinetics of adjunctive topiramate in infants (1–24 months) with refractory partial-onset seizures (POS); also to evaluate safety and tolerability of topiramate in the dose range of 3–25 mg/kg/day. Meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::967e8fc149f13172daa99a3f82a4be7f
https://doi.org/10.1111/epi.12019
https://doi.org/10.1111/epi.12019